carvedilol has been researched along with acetaminophen in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Benassi, JC; Filho, DW; Guidi, DB; Pedrosa, RC; Ronsein, GE | 1 |
| Pisklak, DM; Szeleszczuk, Ł; Zielińska-Pisklak, M | 1 |
| Abdel-Kawy, HS | 1 |
| Cao, Q; Li, M; Teng, H; Wang, C; Wu, X; Yuan, Z; Zhou, L | 1 |
1 review(s) available for carvedilol and acetaminophen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for carvedilol and acetaminophen
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Cytoprotective effects of carvedilol against oxygen free radical generation in rat liver.
Topics: Acetaminophen; Alanine Transaminase; Analgesics, Non-Narcotic; Animals; Antioxidants; Aspartate Aminotransferases; Carbazoles; Carvedilol; DNA Damage; Free Radicals; Liver; Male; Oxidative Stress; Oxygen; Propanolamines; Rats; Rats, Wistar | 2005 |
Application of
Topics: Acetaminophen; Carbazoles; Carbon-13 Magnetic Resonance Spectroscopy; Carvedilol; Cellulose; Dosage Forms; Excipients; Propanolamines; Sorbitol | 2016 |
Effect of carvedilol versus propranolol on acute and chronic liver toxicity in rats.
Topics: Acetaminophen; Adrenergic beta-Antagonists; Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Carbon Tetrachloride; Carvedilol; Chemical and Drug Induced Liver Injury; Chemical and Drug Induced Liver Injury, Chronic; Glutathione; Hepatic Stellate Cells; Liver; Liver Cirrhosis, Experimental; Male; Malondialdehyde; Oxidative Stress; Propranolol; Rats, Wistar; Tumor Necrosis Factor-alpha | 2021 |
Novel carvedilol-loaded pro-phytomicelles: formulation, characterization and enhanced protective efficacy against acetaminophen-inducedliverinjury in mice.
Topics: Acetaminophen; Administration, Oral; Animals; Biological Availability; Carvedilol; Drug Carriers; Mice; Micelles; Nanoparticles; Solubility; Water | 2022 |